CERO THERAPEUTICS HOLDINGS, INC. Income Tax Expense (Benefit), Continuing Operations, Discontinued Operations
CERO THERAPEUTICS HOLDINGS, INC. (CERO) reported Income Tax Expense (Benefit), Continuing Operations, Discontinued Operations of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-24.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems · last filed 2023-03-24
- CERO THERAPEUTICS HOLDINGS, INC. income tax expense (benefit), continuing operations, discontinued operations for fiscal 2022 was $0.00.
| Period end | Income Tax Expense (Benefit), Continuing Operations, Discontinued Operations 7 month | Income Tax Expense (Benefit), Continuing Operations, Discontinued Operations 12 month |
|---|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-03-24 | |
| 2021-12-31 | -$16.87K 10-K · filed 2023-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |